logo

BGLC

BioNexus Gene Lab·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

BGLC fundamentals

BioNexus Gene Lab (BGLC) released its earnings on Aug 18, 2025: revenue was 2.26M (YoY +14.46%), beat estimates; EPS was -0.34 (YoY -3190.91%), missed estimates.
Revenue / YoY
2.26M
+14.46%
EPS / YoY
-0.34
-3190.91%
Report date
Aug 18, 2025
EPS
Revenue

Revenue & Expenses

BGLC has released its 2025 Q3 earnings report, with revenue of 2.54M, reflecting a YoY change of -3.29%, and net profit of -708.99K, showing a YoY change of 47.30%. The Sankey diagram below clearly presents BGLC's revenue sources and cost distribution.

Key Indicators

BioNexus Gene Lab (BGLC) key financial stats and ratios, covering profitability, financial health, and leverage.
BioNexus Gene Lab (BGLC)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
BioNexus Gene Lab (BGLC)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
BioNexus Gene Lab (BGLC)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does BioNexus Gene Lab (BGLC) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track BioNexus Gene Lab (BGLC) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield